TOI.NASDAQOncology Institute, INC

10-Q: The Oncology Institute Reports Q1 2025 Results, Revenue Increases Amid Strategic Financial Moves

Sentiment:

Quarterly Report

đź“‹All filings for Oncology Institute, INC
đź”’Login to Follow

The Oncology Institute's Q1 2025 results show a revenue increase driven by dispensary growth, alongside strategic debt management and a private placement to bolster liquidity.

Capital raiseThe company entered into a securities purchase agreement with accredited investors for a private placement that resulted in gross proceeds of approximately $16.5 million before deducting placement agent fees and offering expenses.Pursuant to the terms of the Securities Purchase Agreement, the Company issued to purchasers in the PIPE units consisting of two shares of common stock (or pre-funded warrants in lieu thereof) and common warrants to purchase one share of common stock (or pre-funded warrants) of the Company at a price of $2.2084 per unit (or $2.2082 in the case of units consisting of prefunded warrants).In connection with the PIPE, certain Lenders under the Company’s Facility Agreement exercised their Participation Rights and entered into an exchange agreement pursuant to which such Lenders agreed to exchange approximately $4,100 aggregate principal amount of the Company’s senior secured convertible notes for 37,232.83 shares of common-equivalent preferred stock (convertible into 3,723,283 shares of common stock) and Common Warrants to purchase 1,861,642 shares of common stock.
Better than expectedThe company's revenue increased by 10.3% year-over-year.The company's Adjusted EBITDA improved by $5.8 million year-over-year.The company's SG&A expenses decreased by 11% year-over-year.

Summary

  • The Oncology Institute (TOI) reported its financial results for the quarter ended March 31, 2025.
  • Total operating revenue increased by 10.3% to $104.4 million, compared to $94.7 million in the same period last year.
  • Patient services revenue saw a slight increase of 1.2%, while dispensary revenue grew significantly by 24.2%.
  • Clinical trials and other revenue decreased by 19.3%.
  • The company experienced a net loss of $19.585 million, similar to the $19.889 million loss in Q1 2024.
  • TOI executed a partial prepayment of its Senior Secured Convertible Notes, resulting in a loss on extinguishment of debt.
  • A private placement generated gross proceeds of approximately $16.5 million.
  • The company is focused on cost reduction and working capital management, leading to an 11% reduction in SG&A expenses compared to the prior year's quarter.
  • TOI believes it has sufficient liquidity to fund operations for at least one year from the issuance date of the financial statements.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive; while the company still reports a net loss, there are improvements in revenue growth, cost management, and strategic financial moves to improve liquidity.

Positives

  • Total operating revenue increased by 10.3% year-over-year.
  • Dispensary revenue showed strong growth, increasing by 24.2%.
  • The company successfully executed a private placement, raising $16.5 million.
  • SG&A expenses were reduced by 11% due to cost-saving measures.
  • The company improved cash flow from operations by approximately $9.8 million from the fourth quarter of 2024 to the current quarter.
  • Adjusted EBITDA improved by $5.8 million to $(5.109) million.

Negatives

  • The company reported a net loss of $19.585 million for the quarter.
  • Clinical trials and other revenue decreased by 19.3%.
  • The company recognized a loss on extinguishment of debt due to the prepayment of Senior Secured Convertible Notes.
  • Cash and cash equivalents decreased from $49.669 million at the beginning of the period to $39.739 million at the end of the period.

Risks

  • The company's ability to generate sufficient taxable income to realize deferred tax assets is uncertain.
  • The company's future liquidity needs may not be met if it cannot generate or obtain needed funds.
  • Inflation could increase costs and negatively impact financial performance.
  • The company is subject to regulatory risks and potential government review and interpretation of healthcare laws and regulations.
  • The company is subject to outside claims and litigation arising in the ordinary course of business.

Future Outlook

The company expects its selling, general, and administrative expenses to increase in absolute dollars in the foreseeable future but decrease as a percentage of revenue over the long term; the company believes it has sufficient liquidity to fund its operations for at least one year from the issuance date of the financial statements.

Management Comments

  • The Company implemented an initiative to eliminate cash burn.
  • Due to efforts towards working capital management that saw improvements across receivables, inventory, and payables, the Company was able to improve cash flow from operations of approximately $9,800 from the fourth quarter of 2024 to the current quarter.
  • The Company generated an 11% reduction in SG&A expenses compared to the prior year same quarter directly as a result of our ongoing efforts to streamline operations, improve efficiency, and optimize our overhead resourcing.

Industry Context

The Oncology Institute operates in the competitive oncology care and management sector, where integrated direct care and cost management are increasingly important; the company's focus on value-based contracts and strategic partnerships aligns with industry trends towards more efficient and outcome-driven healthcare delivery.

Comparison to Industry Standards

  • It is difficult to compare the results to industry standards as the company has a unique business model.
  • Competitors such as US Oncology, McKesson, and other large oncology networks may have different financial reporting structures and business focuses.
  • The company's focus on integrated care and cost management is a growing trend in the industry, but specific benchmarks for this approach are still evolving.
  • The company's performance should be evaluated in the context of its specific market conditions, patient demographics, and contractual arrangements.

Related Party Transactions

  • Related party transactions include payments for consulting services provided to the Company, clinical trials, board fees and expenses.
  • Related party payments for the three months ended March 31, 2025 and 2024 were board fees to Karen M Johnson, Anne M. McGeorge, Mohit Kaushal, Maeve O'Meara Duke, M33 Growth LLC (Gabe Ling), Mark L. Pacala, and Brad Hively.

Stakeholder Impact

  • Shareholders may be impacted by the private placement and debt management activities.
  • Employees may be impacted by cost reduction initiatives and changes in the clinical trials segment.
  • Patients should see continued access to oncology care services.
  • Payors may benefit from the company's focus on cost management and value-based contracts.

Next Steps

  • The Clinical Trials segment will be operated by Helios in its entirety under a profit sharing arrangement with the Company, effective May 5, 2025.
  • The company will continue to focus on cost reduction and working capital management.
  • The company will continue to reevaluate the continued need for a valuation allowance.

Key Dates

DateDescription
2007The Oncology Institute, Inc. (TOI) originally founded.
January 2, 2019The Company issued and adopted the 2019 Non-Qualified Stock Option Plan (the 2019 Plan).
March 10, 2020Warrant Agreement, dated March 10, 2020, by and between DFP and Continental Stock Transfer & Trust Company, as warrant agent
June 28, 2021Agreement and Plan of Merger, dated as of June 28, 2021, by and among DFP Healthcare Acquisitions Corp., Orion Merger Sub I, Inc., Orion Merger Sub II, LLC and TOI Parent, Inc.
November 12, 2021Date of original D&O insurance coverage.
November 18, 2021Amended and Restated Certificate of Incorporation and Bylaws of The Oncology Institute, Inc.
November 22, 2021Certificate of Designation of Series A Common Stock Equivalent Convertible Preferred Stock
December 12, 2021Warrants became exercisable 30 days from the completion of the Business Combination.
August 9, 2022TOI entered into a Facility Agreement with certain lenders (Lenders) and Deerfield Partners L.P. (Agent), pursuant to which, TOI borrowed cash loans from the Lenders in the amount of $110,000.
October 1, 2022Interest shall be paid in cash quarterly in arrears commencing on October 1, 2022.
December 31, 2024End of fiscal year 2024.
February 26, 2025The Company, the Lenders, and the Agent, entered into the Limited Consent and Amendment No. 1 to Facility Agreement (the Consent and Amendment), which amended the Facility Agreement, dated as of August 9, 2022.
March 24, 2025The Company entered into a securities purchase agreement (the Securities Purchase Agreement) with accredited investors for a private placement that resulted in gross proceeds of approximately $16,500.
March 25, 2025Certificate of Correction to Certificate of Designation of Preferences, Rights and Limitations of Series A Common Stock Equivalent Convertible Preferred Stock
March 26, 2025Registration Rights Agreement, dated March 26, 2025, by and among The Oncology Institute, Inc. and the investors signatory thereto
March 31, 2025End of Q1 2025 reporting period.
March 31, 2025The Company entered into a Research Services Agreement 'RSA' with Helios CR, Inc. (Helios), effective May 5, 2025, in which the Clinical Trials segment will be operated by Helios in its entirety under a profit sharing arrangement with the Company.
May 5, 2025Effective date of the Research Services Agreement (RSA) with Helios CR, Inc.
May 7, 2025As of May 7, 2025, the registrant had 89,234,112 shares of common stock outstanding.
May 14, 2025Date of signatures on the 10Q filing.

Keywords

Oncology Institute, financial results, Q1 2025, revenue, dispensary, private placement, debt, liquidity, net loss, EBITDA, cost reduction, healthcare

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.